You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Targeting alpha particle-emitting radionuclides to the nuclei of cancer cells

    SBC: ALPHAMED, INC            Topic: N/A

    DESCRIPTION (provided by applicant): This proposal outlines a body of research to evaluate the cytotoxicity and therapeutic efficacy of radiolabeled alpha-melanocyte stimulating hormone (a-MSH) peptide analogs that target a-particle emitting radioisotopes to the nuclei of melanoma cells. The selective targeting of alpha-particle emitting radioisotopes for cancer therapy is emerging as an exciting ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  2. Processing Ac-227 sources for lead-212 and radium-223 required by cancer research

    SBC: ALPHAMED, INC            Topic: N/A

    DESCRIPTION (provided by applicant): NIH sponsored cancer researchers have been obtaining promising results using molecules radiolabeled with lead-212 in treatment for metastatic melanoma and disseminated colon and pancreatic cancers. Another isotope, radium-223 is being used in clinical trials in treatment of skeletal metastases. There is no effective therapy for these diseases. Together 199,280 ...

    STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health
  3. A Pb-212 Generator Using Resistant Substrate and Rn Cold Trapping

    SBC: ALPHAMED, INC            Topic: N/A

    DESCRIPTION (provided by applicant): Targeted Pb-212 therapy in preclinical animal tests has shown a cure in groups receiving the highest dose of this therapy. Scaling the dose that was most efficacious in animal studies to people would bring the human dose required from 50 to 100 mCi. This application will research an approach that would provide a generator system that would support these require ...

    STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  4. N/A

    SBC: AMRON CORPORATION            Topic: N/A

    N/A

    STTR Phase I 2000 Department of Health and Human ServicesNational Institutes of Health
  5. Night Alert Prompting System

    SBC: AMRON CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): The long-term aim of this program of research is to develop a Night Alert Prompting System (NAPS) that can be used by caregivers of home-dwelling cognitively impaired (CI) individuals to prevent nighttime injuries and unattended exits, improve caregiver sleep, reduce caregiver worry, and thereby delay institutionalization of the CI individuals. The primary func ...

    STTR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  6. Night Alert Prompting System

    SBC: AMRON CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): The long-term aim of this program of research is to develop a Night Alert Prompting System (NAPS) that can be used by caregivers of home-dwelling cognitively impaired (CI) individuals to prevent nighttime injuries and unattended exits, improve caregiver sleep, reduce caregiver worry, and thereby delay institutionalization of the CI individuals. The primary func ...

    STTR Phase II 2003 Department of Health and Human ServicesNational Institutes of Health
  7. ANTI-ANDROGENIC MECHANISM OF A NEW COMPOUND

    SBC: ANDROSCIENCE CORPORATION            Topic: N/A

    DESCRIPTION (provided by applicant): Androgen blockage therapy may relieve the symptom of an advanced, localized prostate tumor; however, once the tumor evolves into a hormone-refractory stage, there is no effective treatment. A continuous activation of AR by antiandrogens (used in androgen blockage therapy) or other "nonconventional" agonists may contribute to prostate cancer progression in patie ...

    STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health
  8. Heterologous Production of Eleutherobin Precursors

    SBC: AMYRIS BIOTECHNOLOGIES            Topic: N/A

    DESCRIPTION (provided by applicant): Terpenoids are a diverse class of natural compounds with equally diverse and potent bioactivities. Because the practical use of terpenoids hinges on the ability to extract or synthesize these compounds, only the most abundant or easily synthesized compounds have been commercially developed. The long-term goal of this Small Business Technology Transfer Phase I p ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  9. Histone Deacetylase Inhibitors for Cancer Treatment

    SBC: Angiogen, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): Histone deacetylases (HDACs) comprise a family of enzymes that catalyze the removal of acetyl groups from lysine residues of histones. They mediate chromatin remodeling and gene expression. HDAC inhibitors are potent inducers of growth arrest, differentiation or apoptic cell death and suppress cell proliferation in a variety of transformed cells in culture and ...

    STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  10. Nano-Ceramic for Metabolic Stem Cell Engineering

    SBC: Angstrom Medica, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The overall objective of this project is to develop a clinically and commercially viable tissue engineered bone construct using nanocrystalline ceramic scaffolds for proliferating and differentiating adipose-derived progenitor cells into cells of the osteogenic lineage. The use of a nanostructured hydroxyapatite (nano-HAP) scaffold offers several advantages for ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government